Crombag MBS - Search Results

1

Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?

Crombag MBS, Koolen SLW, Wijngaard S, Joerger M, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR. Crombag MBS, et al. Pharm Res. 2019 Oct 15;36(12):163. doi: 10.1007/s11095-019-2697-1. Pharm Res. 2019. PMID: 31617004

2

Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter?

Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Crombag MBS, et al. Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26. Br J Clin Pharmacol. 2018. PMID: 30068020 Free PMC article.

3

Impact of age on exposure to oral antiandrogen therapies in clinical practice.

Crombag MBS, van Nuland M, Bergman AM, Rosing H, Schellens JHM, Huitema ADR, Beijnen JH. Crombag MBS, et al. Prostate Cancer Prostatic Dis. 2019 Mar;22(1):168-175. doi: 10.1038/s41391-018-0096-z. Epub 2018 Oct 2. Prostate Cancer Prostatic Dis. 2019. PMID: 30279580

4

Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.

Crombag MBS, de Vries Schultink AHM, Koolen SLW, Wijngaard S, Joerger M, Schellens JHM, Dorlo TPC, van Erp NP, Mathijssen RHJ, Beijnen JH, Huitema ADR. Crombag MBS, et al. Pharm Res. 2019 Jan 7;36(2):33. doi: 10.1007/s11095-018-2563-6. Pharm Res. 2019. PMID: 30617624

5

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Crombag MBS, de Vries Schultink AHM, van Doremalen JGC, Otten HM, Bergman AM, Schellens JHM, Beijnen JH, Huitema ADR. Crombag MBS, et al. Drugs Aging. 2019 Apr;36(4):379-385. doi: 10.1007/s40266-019-00643-2. Drugs Aging. 2019. PMID: 30734241

6

Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort.

de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, Huitema ADR, Beijnen JH. de Vries Schultink AHM, et al. Among authors: crombag mbs. Cancer Med. 2019 Apr;8(4):1406-1415. doi: 10.1002/cam4.2003. Epub 2019 Feb 22. Cancer Med. 2019. PMID: 30802002 Free PMC article.

7

Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials.

Crombag MBS, Haanen JBAG, Baas P, Beijnen JH, Huitema ADR. Crombag MBS, et al. J Geriatr Oncol. 2020 Apr;11(3):529-532. doi: 10.1016/j.jgo.2019.06.001. Epub 2019 Jun 14. J Geriatr Oncol. 2020. PMID: 31208830 No abstract available.

8

Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study.

Crombag MBS, Dorlo TPC, van der Pan E, van Straten A, Bergman AM, van Erp NP, Beijnen JH, Huitema ADR. Crombag MBS, et al. Pharm Res. 2019 Nov 15;36(12):181. doi: 10.1007/s11095-019-2706-4. Pharm Res. 2019. PMID: 31732882

9

The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients.

van Doorn L, Crombag MBS, Rier HN, van Vugt JLA, van Kesteren C, Bins S, Mathijssen RHJ, Levin MD, Koolen SLW. van Doorn L, et al. Among authors: crombag mbs. Pharmaceuticals (Basel). 2021 Jan 9;14(1):47. doi: 10.3390/ph14010047. Pharmaceuticals (Basel). 2021. PMID: 33435449 Free PMC article.

10

Is age just a number? A population pharmacokinetic study of gemcitabine.

Boosman RJ, Crombag MBS, van Erp NP, Beijnen JH, Steeghs N, Huitema ADR. Boosman RJ, et al. Among authors: crombag mbs. Cancer Chemother Pharmacol. 2022 May;89(5):697-705. doi: 10.1007/s00280-022-04431-5. Epub 2022 Apr 15. Cancer Chemother Pharmacol. 2022. PMID: 35426526

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page